Medical Research Unit in Infectious Diseases, Hospital de Pediatría, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Pharmacology Department, CINVESTAV, Mexico City, Mexico.
J Cancer Res Clin Oncol. 2020 Aug;146(8):2029-2040. doi: 10.1007/s00432-020-03266-y. Epub 2020 May 30.
Expression microarrays are powerful technology that allows large-scale analysis of RNA profiles in a tissue; these platforms include underexploited detection scores outputs. We developed an algorithm using the detection score, to generate a detection profile of shared elements in retinoblastoma as well as to determine its transcriptomic size and structure.
We analyzed eight briefly cultured primary retinoblastomas with the Human transcriptome array 2.0 (HTA2.0). Transcripts and genes detection scores were determined using the Detection Above Background algorithm (DABG). We used unsupervised and supervised computational tools to analyze detected and undetected elements; WebGestalt was used to explore functions encoded by genes in relevant clusters and performed experimental validation.
We found a core cluster with 7,513 genes detected and shared by all samples, 4,321 genes in a cluster that was commonly absent, and 7,681 genes variably detected across the samples accounting for tumor heterogeneity. Relevant pathways identified in the core cluster relate to cell cycle, RNA transport, and DNA replication. We performed a kinome analysis of the core cluster and found 4 potential therapeutic kinase targets. Through analysis of the variably detected genes, we discovered 123 differentially expressed transcripts between bilateral and unilateral cases.
This novel analytical approach allowed determining the retinoblastoma transcriptomic size, a shared active transcriptomic core among the samples, potential therapeutic target kinases shared by all samples, transcripts related to inter tumor heterogeneity, and to determine transcriptomic profiles without the need of control tissues. This approach is useful to analyze other cancer or tissue types.
表达微阵列是一种强大的技术,可允许对组织中的 RNA 谱进行大规模分析;这些平台包括利用不足的检测分数输出。我们开发了一种使用检测分数的算法,以生成视网膜母细胞瘤中共享元素的检测谱,并确定其转录组大小和结构。
我们使用人类转录组阵列 2.0(HTA2.0)分析了 8 个短暂培养的原发性视网膜母细胞瘤。使用检测超过背景算法(DABG)确定转录物和基因的检测分数。我们使用无监督和有监督的计算工具来分析检测到和未检测到的元素;使用 WebGestalt 探索相关簇中基因编码的功能,并进行实验验证。
我们发现了一个核心簇,其中包含 7513 个基因,这些基因在所有样本中均被检测到并共享,在一个共同缺失的簇中包含 4321 个基因,在跨样本的可变检测中包含 7681 个基因,这些基因共同构成了肿瘤异质性。核心簇中鉴定出的相关途径与细胞周期、RNA 转运和 DNA 复制有关。我们对核心簇进行了激酶组分析,发现了 4 个潜在的治疗激酶靶标。通过对可变检测基因的分析,我们在双侧和单侧病例之间发现了 123 个差异表达的转录本。
这种新的分析方法允许确定视网膜母细胞瘤转录组的大小、样本之间共享的活跃转录组核心、所有样本共享的潜在治疗性激酶靶标、与肿瘤间异质性相关的转录本,以及无需对照组织即可确定转录组谱。这种方法可用于分析其他癌症或组织类型。